The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone
Open Access
- 3 July 2026
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (10) , 3656-3665
Abstract
Aim: Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment versus participants with normal hepatic function. Methods: Participants with mild and moderate hepatic impairment (Child–Pugh Class A [ n = 8] and Child–Pugh Class B [ n = 8]) were compared with group matched controls with normal hepatic function [ n = 9]. Eligible participants received a single oral dose of 50‐mg balcinrenone. Blood and urine samples were collected. Safety and tolerability were monitored. Results: In participants with mild hepatic impairment, balcinrenone exposure (area under the plasma concentration–time curve [AUC] and maximum plasma concentration [ C max ]) was similar compared with participants with normal hepatic function. In participants with moderate hepatic impairment, C max was similar, but there was a slight and statistically significant 30% (90% CI 4%–61%) increase in AUC compared with participants with normal hepatic function. Balcinrenone was well tolerated. All reported adverse events were of mild to moderate intensity. Conclusions: Compared with participants with normal hepatic function, balcinrenone exposure was similar in participants with mild hepatic impairment. AUC, but not C max , was slightly increased in participants with moderate hepatic impairment. We do not consider the minor AUC increase seen in participants with moderate hepatic impairment to be clinically relevant. Thus, we would not recommend any dose adjustment for patients with mild or moderate hepatic impairment.Keywords
Funding Information
- AstraZeneca
This publication has 17 references indexed in Scilit:
- The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenoneBritish Journal of Clinical Pharmacology, 2025
- Balcinrenone Plus Dapagliflozin in Patients with Heart Failure and Chronic Kidney Disease: Results from the Phase 2b MIRACLE TrialEuropean Journal of Heart Failure, 2024
- 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2023
- New Creatinine- and Cystatin C–Based Equations to Estimate GFR without RaceNew England Journal of Medicine, 2021
- Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology, 2021
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicineEuropean Heart Journal, 2020
- Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney DiseaseThe American Journal of Cardiology, 2020
- Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection FractionJACC, 2014
- Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose StudyClinical Therapeutics, 2011
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973